About Enavate Sciences
Enavate Sciences is a company based in United States founded in 2022. Enavate Sciences has raised $300 million across 1 funding round from investors including Patient Square Capital. Enavate Sciences offers products and services including Investment Services. Enavate Sciences operates in a competitive market with competitors including Indegene, Zuellig Pharma, IntegriChain, Fishawack and Clinigen, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$300 M (USD)
in 1 rounds
-
Latest Funding Round
$300 M (USD), Series D
May 02, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enavate Sciences
Enavate Sciences offers a comprehensive portfolio of products and services, including Investment Services.
Provides funding and support to life sciences companies for growth.
People of Enavate Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of Enavate Sciences
Enavate Sciences has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series D round of $300 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enavate Sciences
Enavate Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Patient Square Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Patient Square Capital is focused on health care investments.
|
Locked | Locked | Locked |
Investor details for Enavate Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enavate Sciences
Investment portfolio details for Enavate Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enavate Sciences
Detailed financials for Enavate Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enavate Sciences Comparisons
Peer comparison for Enavate Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enavate Sciences
Enavate Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indegene, Zuellig Pharma, IntegriChain, Fishawack and Clinigen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Suite solutions are provided for payers and healthcare providers.
|
|
| Locked | Locked | Locked |
Healthcare access in Asia is enhanced by Zuellig Pharma.
|
|
| Locked | Locked | Locked |
Inventory, order and customer relationship management solution for life science suppliers.
|
|
| Locked | Locked | Locked |
Fully integrated cross-border services are delivered to global pharmaceutical organizations.
|
|
| Locked | Locked | Locked |
Specialty medicines are supplied via clinical trials and access programs.
|
|
| Locked | Locked | Locked |
Technology-based consultancy and product development services are provided.
|
Detailed competitors of Enavate Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enavate Sciences
Complete news archive for Enavate Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enavate Sciences
Enavate Sciences was founded in 2022.
Enavate Sciences is headquartered in United States.
James Boylan is the current CEO of Enavate Sciences.
Enavate Sciences is a funded company, having raised a total of $300M across 1 funding round to date.
Enavate Sciences was founded in 2022 and is headquartered in the United States. Consulting services are delivered to pharmaceutical and biotechnology firms, focusing on enhancements to drug discovery and development processes. Market assessment services are also offered to evaluate commercial potential and strategic positioning. Operations center on advisory support for lifecycle management in the life sciences sector, with leadership provided by CEO James Boylan.
Enavate Sciences's top competitors include Indegene, Zuellig Pharma and IntegriChain.
Enavate Sciences offers Investment Services.
Enavate Sciences has 1 investor. Key investors include Patient Square Capital.